Explore the latest in breast cancer, including recent guidelines and advances in screening, genetic testing, and precision treatment.
This economic evaluation modeled the cost-effectiveness of 5 neoadjuvant-adjuvant treatment strategies for women with ERBB2-positive breast cancer.
This cohort study evaluates the association of different adjuvant therapies with survival outcomes in patients with triple-negative breast cancer.
This systematic review and meta-analysis uses data from studies retrieved from a Cochrane Library, ScienceDirect, PubMed, and Embase search to investigate the association of circulating tumor DNA with disease-free survival in patients with breast cancer.
This cohort study investigates the long-term reproductive outcomes in women who did or did not undergo fertility preservation at the time of breast cancer diagnosis.
This prognostic study describes a multivariate linear regression model that combines mammographic breast density with patient, cancer, and treatment factors to identify the possible posttreatment volume of lymphedema in patients with breast cancer.
This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count–driven choice for first-line treatment among women with hormone receptor–positive, ERBB2-negative metastatic breast cancer.
This randomized clinical trial evaluates clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.
This cross-sectional study assesses whether the rate of positive BRCA test results changed between 2008 and 2018 among older women in the United States.
This cross-sectional study examines the association between neighborhood deprivation and estimates of epigenetic age acceleration and genome-wide methylation among women in the US and Puerto Rico.
This study evaluates the differential associations of surgery with quality of life and psychosocial outcomes among women with breast cancer from 1 to 5 years following diagnosis.
This decision analysis estimates the lifetime incremental incidence of hereditary breast and ovarian cancer and the quality-adjusted life-years, costs, and cost-effectiveness of hereditary breast and ovarian cancer genomic screening in an unselected population vs family history–based testing.
This prognostic study examines the use of endothelial cell phosphorylated-focal adhesion kinase as a biomarker for chemotherapy sensitivity in women with breast cancer.
This systematic review and meta-analysis examines the reoperation rates reported in the literature before and after publication of the 2014 Society of Surgical Oncology–American Society for Radiation Oncology guideline for surgical management of invasive cancer.
This cohort study describes the incidence rates of 4 breast cancer molecular subtypes stratified by race/ethnicity among women in the US.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: